Amnion-loaded contact lens and preparation method and application thereof

Abstract

The invention provides an amnion-loaded contact lens and a preparation method and application thereof. According to the invention, the bonding mode of the amniotic membrane and the contact lens is innovated, the previous mode of simply bonding the amniotic membrane and the contact lens by using medical biological glue is changed, the bonding procedure of the amniotic membrane and the contact lens is simplified, and the method is suitable for industrial application; the problems that the mechanical supporting force is reduced, the amniotic membrane is broken and the coverage is uneven due to the fact that the ocular surface coverage time of a traditional suture type amniotic membrane is prolonged are solved; in the aspect of material optimization and selection, the basic requirement of non-toxicity and harmlessness of the adhesive is met, and meanwhile, the requirements of biocompatibility and the oxygen permeability of the cornea on the contact lens are also considered; the amniotic membrane is more comfortable in the using process, complex operation procedures are not needed, and stimulation caused by no suture is avoided; the design scheme that the contact lens is used as the amniotic membrane support enables the amniotic membrane lens to provide better support and protection for the covered ocular surface.

Description

Technical Field

[0001] The present invention generally relates to the field of biomedical materials, and in particular, to an amniotic membrane-loaded contact lens and a preparation method and application thereof. Background Art

[0002] Corneal epithelial defects are common clinical problems in ophthalmology, often caused by a variety of non-infectious causes, such as mechanical trauma, chemical burns, dry eyes, neurotrophic keratitis, autoimmune diseases, etc. If corneal epithelial defects are not effectively repaired for a long time, it may cause a series of serious complications, including corneal ulcers and corneal perforations, which will not only seriously affect vision, but may even cause blindness.

[0003] The amniotic membrane is the inner layer of the placenta and has unique biological properties. It is widely used in the field of ophthalmology. Its main advantages include: anti-inflammatory properties: the amniotic membrane contains a variety of anti-inflammatory factors, which can reduce inflammatory reactions and help treat ocular surface diseases; anti-scarring: the matrix components in the amniotic membrane can inhibit the activity of fibroblasts and prevent scar formation; promote healing: the amniotic membrane is rich in growth factors, which can promote cell proliferation and migration and accelerate wound healing; antibacterial properties: the amniotic membrane has certain antibacterial activity, which can reduce the risk of infection.

[0004] Due to these advantages, amniotic membrane is used in a variety of ophthalmic surgeries and treatments. Traditional amniotic membrane transplantation is to fix the amniotic membrane to the corneal surface by suturing under topical anesthesia or peribulbar block anesthesia. However, the suturing fixation method has disadvantages such as complicated operation, long operation time, and foreign body stimulation of sutures. The suturing process may also increase the risk of infection and may cause additional mechanical damage to the patient's cornea. In addition, if the amniotic membrane at the suture site is damaged, it will rupture and dissolve prematurely, and a second operation may be required, increasing the patient's pain and economic burden. Summary of the invention

[0005] The present invention prepares a wearable amniotic membrane contact lens by recombining the amniotic membrane into a pre-polymerized liquid and combining it with a specially treated contact lens. This can solve the problems of the inconvenience and poor comfort of existing amniotic membrane applications, while enhancing the treatment effect and improving the patient's wearing experience, providing an effective solution for clinical ophthalmic treatment.

[0006] In a first aspect of the present invention, a method for preparing an amniotic membrane-loaded contact lens is provided, comprising:

[0007] S1. Preparing amniotic membrane recombinant prepolymer solution: mixing methacrylated gelatin, lithium phenyl-2,4,6-trimethylbenzoylphosphinate and amniotic membrane powder to obtain a mixed solution;

[0008] S2. After sterilizing the mixed solution, an amniotic membrane reconstitution prepolymer solution is obtained;

[0009] S3. Preparing a contact lens treatment solution: mixing methacrylated gelatin and lithium phenyl-2,4,6-trimethylbenzoylphosphinate to obtain a contact lens treatment solution;

[0010] S4. Pre-treating the contact lens: soaking the contact lens in a contact lens treatment solution to obtain a pre-treated contact lens;

[0011] S5. The amniotic membrane recombinant prepolymer solution obtained in step S2 is uniformly coated on the surface of the pretreated contact lens in step S4; and light is irradiated to cause in-situ curing and cross-linking to obtain an amniotic membrane-loaded contact lens.

[0012] Preferably, the pore diameter of the methacrylated gelatin after photocuring is between 10um and 200um, and the porosity is 30-60%.

[0013] More preferably, the pore diameter of the methacrylated gelatin after photocuring is between 100um and 200um, and the porosity is 50-60%.

[0014] Preferably, the contact lens is a soft hydrophilic contact lens with a water content of 34-40%.

[0015] Preferably, in step S1, the mass percentage concentrations of methacryloyl gelatin, lithium phenyl-2,4,6-trimethylbenzoylphosphinate and amniotic membrane powder in the mixed solution are 6-8%, 0.2-0.5% and 20-50%, respectively.

[0016] Preferably, in step S3, the mass percentage concentrations of methacrylated gelatin and lithium phenyl-2,4,6-trimethylbenzoylphosphinate in the contact lens treatment solution are 6-8% and 0.2-0.5%, respectively.

[0017] Preferably, in step S4, the contact lens is completely immersed in the contact lens treatment solution at 15-40° C. for 20-60 minutes.

[0018] Preferably, in step S5, the conditions of illumination are: wavelength between 320 and 400 nanometers, and illumination for 30-120 seconds.

[0019] In a second aspect of the present invention, there is provided an amniotic membrane-loaded contact lens produced according to the above method for producing an amniotic membrane-loaded contact lens.

[0020] In the third aspect of the present invention, a method for preparing the above-mentioned amniotic membrane-loaded contact lens and the use of the amniotic membrane-loaded contact lens in preparing a medical device for treating or alleviating corneal epithelial defects and promoting corneal epithelial cell repair are provided.

[0021] The wearable amniotic membrane-loaded contact lens of the present invention has the following beneficial effects:

[0022] 1. The bonding method of amniotic membrane and contact lens has been innovated, changing the previous method of simply bonding amniotic membrane and contact lens with medical biological glue, simplifying the bonding procedure of amniotic membrane and contact lens, and making it suitable for industrial application.

[0023] 2. It solves the problem of traditional sutured amniotic membrane, which causes the mechanical support to decrease as the covering time of the ocular surface increases, and leads to amniotic membrane rupture and uneven covering.

[0024] 3. The present invention not only meets the basic requirement of non-toxic and harmless adhesive in terms of material optimization and selection, but also takes into account the biocompatibility and corneal oxygen permeability requirements of contact lenses.

[0025] 4. The use of amniotic membrane is more comfortable, does not require complicated surgical procedures, and does not cause irritation caused by sutures.

[0026] 5. The design of using contact lens as amniotic membrane support enables the amniotic membrane to provide better support and protection for the covered ocular surface. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is a real photo of wearable amniotic contact lens.

[0028] Figure 2 This is a gross photograph of the rabbit cornea before and after wearing the amniotic membrane contact lens in Comparative Example 1.

[0029] Figure 3 This is the sodium fluorescein staining image of the cornea in Comparative Example 1.

[0030] Figure 4 It is the healing rate of the cornea in Comparative Example 1.

[0031] Figure 5 This is the corneal slit lamp photography and sodium fluorescein staining image of the cornea of ​​the PEGDA group in Comparative Example 2.

[0032] Figure 6 This is the corneal slit lamp photo and sodium fluorescein staining image of the cornea of ​​the ordinary GelMA group in Comparative Example 2. DETAILED DESCRIPTION

[0033] In order to solve the technical problems of the existing single amniotic membrane transplantation method, complicated operation, low patient comfort and limited protection performance, the present invention provides a wearable amniotic membrane-loaded contact lens and its preparation method and application. The purpose of the present invention is achieved through the following technical solutions.

[0034] The method for preparing a wearable amniotic membrane-loaded contact lens (amniotic membrane contact lens) comprises:

[0035] S1. Preparing amniotic membrane recombinant prepolymer solution: mixing methacrylated gelatin (GelMA hydrogel), lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) and amniotic membrane powder to obtain a mixed solution;

[0036] Preferably, the mass percentage concentrations of GelMA hydrogel, lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) and amniotic membrane powder in the mixed solution are 6-8%, 0.2-0.5% and 20-50%, respectively; more preferably, the mass percentage concentrations are 6-8%, 0.2-0.5% and 20-30%, respectively.

[0037] Preferably, the pore diameter of the GelMA hydrogel after photocuring is between 10 um and 200 um, and the porosity is 30-60%.

[0038] More preferably, after photocuring, the pore diameter of the GelMA hydrogel is between 100 um and 200 um, and the porosity is 50-60%.

[0039] In the present invention, there is no limitation on the solvent used to dissolve the GelMA hydrogel, LAP and amniotic membrane powder, and the solvent may be water, distilled water or deionized water.

[0040] The present invention has no limitation on the uniform mixing method, and those skilled in the art can complete the mixing according to conventional operations.

[0041] S2. After sterilizing the mixed solution, an amniotic membrane reconstitution prepolymer solution is obtained;

[0042] The present invention has no limitation on the sterilization method, and those skilled in the art can perform the sterilization according to conventional operations. Preferably, pasteurization is used.

[0043] S3. Preparing a contact lens treatment solution: mixing the GelMA hydrogel and LAP to obtain a contact lens treatment solution;

[0044] Preferably, the mass percentage concentrations of GelMA hydrogel and LAP in the treatment solution are 6-8% and 0.2-0.5%, respectively.

[0045] In the present invention, there is no limitation on the solvent used to dissolve the GelMA hydrogel and LAP, and the solvent may be water, distilled water, deionized water, or PBS phosphate buffer.

[0046] The present invention has no limitation on the uniform mixing method, and those skilled in the art can complete the mixing according to conventional operations.

[0047] S4. Pre-treating the contact lens: soaking the contact lens in a contact lens treatment solution to obtain a pre-treated contact lens;

[0048] The present invention has no limitation on the immersion method, and those skilled in the art can perform the immersion according to conventional operations. Optionally, the contact lens is completely immersed in the contact lens treatment solution at 15-40° C. for 20-60 minutes.

[0049] S5. The amniotic membrane recombinant prepolymer solution obtained in step S2 is uniformly coated on the surface of the pretreated contact lens in step S4; and light is irradiated to cause in-situ curing and cross-linking to obtain a wearable amniotic membrane contact lens.

[0050] The present invention has no limitation on the coating amount of amniotic membrane recombinant prepolymer solution. Those skilled in the art can coat different amounts of amniotic membrane recombinant prepolymer solution on the surface of the pretreated contact lens (e.g., the inner surface optical zone, the entire inner surface area, or the entire inner and outer surfaces) according to actual needs.

[0051] Preferably, the amniotic membrane reconstitution prepolymer solution is applied to the inner surface of the pretreated contact lens.

[0052] The loading amount of amniotic membrane can be adjusted by the concentration and coating amount of amniotic membrane recombinant prepolymer solution. For example, 90ul of amniotic membrane recombinant prepolymer solution containing 20%-30% amniotic membrane powder is coated on the inner surface of the contact lens for curing and cross-linking, that is, the loading amount of amniotic membrane per amniotic membrane contact lens is 23mg / lens.

[0053] In the present invention, the optical zone on the inner surface of the contact lens refers to the central part of the optical zone on the rear surface of the contact lens, the radius of curvature of which is designed to match the shape of the cornea to ensure that light passing through this area can be clearly focused on the retina.

[0054] Preferably, the contact lens is a soft hydrophilic contact lens with a water content of 34-40%. When the water content is greater than 40%, it is not conducive to the adhesion of the amniotic membrane reconstitution prepolymer solution.

[0055] Preferably, the conditions of illumination are: wavelength between 320 and 400 nanometers, and illumination for 30-120 seconds.

[0056] In the present invention, the above method further includes a pre-treatment step of the amniotic membrane, including: taking fresh amniotic membrane, washing it with sterile saline and then rinsing it in antibiotic saline; scraping off the sponge layer, part of the fibroblast layer and serous exudate under a microscope; attaching a sterile nitrocellulose membrane (NC membrane) thereon with the amniotic epithelial surface facing upward; and trimming it to a suitable size according to actual needs.

[0057] In the present invention, the above method further includes the steps of preparing amniotic membrane powder, including: pre-freezing the sterile treated amniotic membrane, for example, placing it in a -80° refrigerator for 20 minutes; freeze-drying the pre-frozen amniotic membrane, for example, treating it in a vacuum freeze dryer at -53° for 48 hours; grinding the freeze-dried amniotic membrane into powder, for example, cutting the amniotic membrane into small pieces and transferring them to a centrifuge tube containing grinding beads, and grinding it into powder using a grinder at 30 times / second, 90s, 3 times.

[0058] In the present invention, the above method further comprises a post-treatment step, namely, washing the reacted amniotic membrane, pre-treated contact lens, and amniotic membrane contact lens: washing them in a buffer solution to remove unreacted reagents and by-products.

[0059] In the present invention, there is no limitation on the buffer used for the washing reaction, and those skilled in the art can select, for example, PBS buffer according to actual conditions.

[0060] In the present invention, there is no limitation on the number and time of cleaning, and those skilled in the art can determine it according to the actual situation, for example, cleaning 3-10 times, each time for 2-60 minutes.

[0061] The technical solution of the present invention is based on the following principle: GelMA (gelatin methacrylate) is a photosensitive biomaterial synthesized by reacting the amine group (-NH2) on the gelatin molecule with methacrylic anhydride (MA) to introduce a methacrylate group (-C(=O)OCH3). This modification gives gelatin the ability to undergo photo-crosslinking, that is, under the irradiation of ultraviolet light, GelMA can quickly form a stable three-dimensional network structure. Porous GelMA hydrogel is a material with a special microstructure, and its porous structure can provide a larger space and a more efficient material exchange channel, which is beneficial to cell proliferation, growth, and the transmission of nutrients and metabolic waste.

[0062] The preparation of porous GelMA hydrogels generally involves mixing GelMA with another polymer to form a two-phase or multiphase system. For example, by mixing GelMA with polyvinyl alcohol (PEO), hydrogels with different porosities can be created. By adjusting the volume fraction of PEO and the mixing time, the pore size and porosity can be controlled. In the present invention, the GelMA hydrogel is a porous GelMA hydrogel with a pore size of 10um-200um and a porosity of 30-60%, so that the amniotic membrane contact lens has good oxygen permeability and can be worn for a long time without causing corneal hypoxia.

[0063] The present invention is further illustrated by the following examples which explain the present invention. The following examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention. Unless otherwise specified, the technical and scientific terms used herein are the meanings generally understood by those of ordinary skill in the art to which the present invention belongs. If no specific conditions are specified in the examples, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.

[0064] Sources

[0065] The amniotic membrane was donated by the Obstetrics Department of the Provincial Hospital.

[0066] High-porosity GelMA hydrogel was purchased from Suzhou Yongqinquan Intelligent Equipment Co., Ltd. The product model is EFL-GM-PR-001, with a porosity / pore size of 30-40% / 10-100um; EFL-GM-PR-002, with a porosity / pore size of 50-60% / 100-200um.

[0067] Invisible corneal contact lenses were purchased from Bausch and Lomb Co., Ltd. The product is a soft hydrophilic contact lens with a water content of 36% and a nominal oxygen permeability coefficient of 68.3×10 -11 (cm 2 / s)[mLO2 / (mL×hPa)], lens diameter: 14mm, base curve radius: 8.6mm, center thickness: 0.07mm.

[0068] Example 1

[0069] To prepare an amniotic membrane contact lens, follow these steps:

[0070] S1. Prepare amniotic membrane reconstitution prepolymer solution: mix high porosity GelMA hydrogel (porous GelMA), lithium phenyl-2,4,6-trimethylbenzoylphosphite (LAP) and amniotic membrane powder evenly to obtain a mixed solution.

[0071] The mass percentage concentrations of high porosity GelMA hydrogel (porous GelMA), lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) and amniotic membrane powder in the mixed solution are 6-8%, 0.2-0.5%, 20-50%, for example, 7%, 0.3%, 25%; 7.5%, 0.4%, 30%; 6%, 0.2%, 20%; 8%, 0.5%, 50%. The solvent is water.

[0072] In order to fully dissolve and mix the substances, the mixed solution can be placed in a 37° constant temperature water bath for 15 minutes, taken out and shaken for 30 seconds to fully mix, and the above steps can be repeated three times according to actual needs.

[0073] S2. Pasteurize the mixed solution to obtain amniotic membrane reconstitution prepolymer solution.

[0074] The sterilization method is: 80° constant temperature water bath, 30 min; 0°C ice water, 5 min; the above steps are repeated 3-5 times.

[0075] S3. Prepare contact lens treatment solution: mix high porosity GelMA hydrogel (porous GelMA) and LAP evenly to obtain contact lens treatment solution.

[0076] The mass percentage concentrations of high porosity GelMA hydrogel (porous GelMA) and LAP in the treatment solution are 6-8% and 0.2-0.5%, for example, 6%, 0.2%; 7%, 0.4%. The solvent is PBS phosphate buffer.

[0077] S4. Pre-treat the contact lens: immerse the contact lens in contact lens treatment solution at room temperature (15-25°C) for 30 minutes to obtain a pre-treated contact lens.

[0078] S5. The amniotic membrane recombinant prepolymer solution obtained in step S2, for example, 80-100ul, 20-30ul, is uniformly coated on the inner surface (the side facing or contacting the ocular surface) of the pretreated contact lens in step S4, and then irradiated under ultraviolet light for 30 seconds to cause in-situ curing and cross-linking to obtain a wearable amniotic membrane-loaded contact lens ( Figure 1 ).

[0079] In order to evenly coat the amniotic membrane recombinant prepolymer solution on the inner surface of the pretreated contact lens, the contact lens coated with the amniotic membrane recombinant prepolymer solution can be placed on the inner surface molding mold, and then irradiated under ultraviolet light to complete in-situ curing and cross-linking. After demolding, a wearable amniotic membrane contact lens is obtained.

[0080] Comparative Example 1

[0081] Twelve New Zealand white rabbits were taken. After anesthesia, the corneal epithelium and basement membrane within 11 mm were scraped with an epithelial knife. Six rabbits were randomly selected to wear the wearable amniotic membrane contact lenses prepared in Example 1 (amniotic membrane contact lenses group); the remaining six rabbits were not treated after surgery (control group). One day and two days after surgery, corneal slit lamp photography and sodium fluorescein staining photography were performed to record the healing of various corneal epithelial conditions, red eyes, secretions and other abnormal conditions. Figure 2 As shown in the figure, the experimental animal before and after wearing the amniotic lens, the contact lens fits well and has good transparency. Figure 3 As shown, 24 hours after surgery, the experimental group showed more natural blinking behavior, very little sticky secretion, and milder inflammatory response because of the protection of wearable amniotic membrane contact lenses; the control group closed their eyes due to epithelial damage, with obvious inflammatory response and severe conjunctival congestion.

[0082] One month after surgery, the healing rates of corneal epithelium in the two groups were calculated using Image J software. Figure 4 ), the results showed that the healing speed of corneal epithelium in the amniotic lens group was significantly faster than that in the blank control group, and the difference was statistically significant.

[0083] Comparative Example 2

[0084] Grouping: Twelve New Zealand white rabbits were randomly divided into three groups, four rabbits in each group, namely porous GelMA group, PEGDA group, and ordinary GelMA group.

[0085] After the rabbits were anesthetized, the corneal epithelium and basement membrane within 11 mm were scraped off with an epithelial knife.

[0086] The porous GelMA group was given the wearable amniotic membrane contact lens prepared in Example 1 after surgery.

[0087] In the PEGDA group, PEGDA-based amnioscopic surgery was performed.

[0088] The difference between the PEGDA-based amniotic membrane lens and the amniotic membrane contact lens prepared in Example 1 is that the pre-treated corneal contact lens is not loaded thereon. Since the oxygen permeability of the PEGDA itself is poor after light curing, loading another layer of corneal contact lens will further reduce the oxygen permeability. At the same time, after curing, 0.2% PEGDA exhibits poor ductility and high brittleness due to its own material characteristics, and cannot be well adapted to the contact lens. The specific preparation steps are as follows:

[0089] Steps S1 and S2 are the same as those in Example 1.

[0090] S3. Take 20-30ul of the amniotic membrane PEGDA mixed solution, for example, 25ul, and add it to the contact lens molding mold, press the mold evenly to mold the amniotic membrane PEGDA mixed solution, and then irradiate under ultraviolet light to complete in-situ curing and cross-linking. After demolding, a PEGDA-based amniotic membrane contact lens is obtained.

[0091] The ordinary GelMA group was given an ordinary GelMA-based amnioscopic lens after surgery.

[0092] The preparation method of the common GelMA-based amniotic membrane contact lens is different from that in Example 1 in that the pre-treated corneal contact lens is not loaded thereon. The steps for preparing the common GelMA-based amniotic membrane contact lens are as follows:

[0093] Steps S1 and S2 are the same as those in Example 1.

[0094] S3. Take 20-30ul of the amniotic membrane GelMA mixed solution, for example, 25ul, and add it to the contact lens molding mold, press the mold evenly to mold the amniotic membrane GelMA mixed solution, and then irradiate under ultraviolet light to complete in-situ curing and cross-linking. After demolding, a GelMA-based amniotic membrane contact lens is obtained.

[0095] Corneal slit lamp photography and sodium fluorescein staining were performed 1, 3, and 5 days after surgery. Figure 5 , Figure 6 ), record the healing conditions of various corneal epithelial cells as well as redness, secretions and other abnormalities.

[0096] The results show:

[0097] Porous GelMA group: No lens detachment occurred during the 36-hour observation after surgery. The porous GelMA group showed a milder inflammatory response, no conjunctival congestion, no ciliary congestion, faster healing, less secretion, and most importantly, no neovascularization.

[0098] In the PEGDA group, due to its greater fragility, most lenses fell off due to lens breakage during the follow-up observation after surgery. In the observation 12 hours after surgery, the lens removal rate reached 50%, in the observation 24 hours after surgery, the lens removal rate increased to 62%, and in the observation 36 hours after surgery, the lens removal rate reached 75%, of which the proportion of lens removal due to lens breakage reached 83%, that is, among the 6 lenses that fell off, 5 were caused by lens breakage due to the excessive fragility of PEGDA.

[0099] Compared with the PEGDA group, the lenses in the ordinary GelMA group had better ductility and rarely fell off due to lens breakage. The main reason for lens falling off was that the material underwent a certain degree of shrinkage after curing, resulting in a certain amount of warping around the lens, affecting the close fit between the lens and the ocular surface. At the same time, its better biocompatibility and amniotic release rate resulted in a faster degradation rate than PEGDA-based amniotic membrane contact lenses, which also accelerated the lens falling off. In the observation 12 hours after surgery, the lens falling off rate reached 37%, and in the observation 24 hours after surgery, the lens falling off rate increased to 50%. In the observation 36 hours after surgery, the lens falling off rate reached 62%, of which the proportion of falling off due to warping reached 40%, that is, 2 of the 5 fallen lenses fell off due to warping, and the remaining 3 fell off due to degradation as the observation time increased.

[0100] The PEGDA group and the ordinary GelMA group showed more severe inflammatory reactions, with severe conjunctival congestion, more secretions, obvious photophobia in the rabbit eyes, and the eyes were tightly closed.

[0101] The above specific implementations do not constitute a limitation on the protection scope of the present invention. It should be understood by those skilled in the art that various modifications, combinations, sub-combinations and substitutions can be made according to design requirements and other factors. Any modification, equivalent substitution and improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing an amniotic membrane-loaded contact lens, comprising: S1. Preparing amniotic membrane recombinant prepolymer solution: mixing methacrylated gelatin, lithium phenyl-2,4,6-trimethylbenzoylphosphinate and amniotic membrane powder to obtain a mixed solution; S2. After sterilizing the mixed solution, an amniotic membrane reconstitution prepolymer solution is obtained; S3. Preparing a contact lens treatment solution: mixing methacrylated gelatin and lithium phenyl-2,4,6-trimethylbenzoylphosphinate to obtain a contact lens treatment solution; S4. Pre-treating the contact lens: soaking the contact lens in a contact lens treatment solution to obtain a pre-treated contact lens; S5. The amniotic membrane recombinant prepolymer solution obtained in step S2 is uniformly coated on the surface of the pretreated contact lens in step S4; and light is irradiated to cause in-situ curing and cross-linking to obtain an amniotic membrane-loaded contact lens.

2. The method for preparing a contact lens according to claim 1, wherein: After photocuring, the pore diameter of methacrylated gelatin is between 10um and 200um, and the porosity is 30-60%.

3. The method for preparing a contact lens according to claim 2, characterized in that: After photocuring, the pore diameter of methacrylated gelatin is between 100um and 200um, and the porosity is 50-60%.

4. The method for preparing a contact lens according to claim 1, wherein: The contact lenses are soft hydrophilic contact lenses with a water content of 34-40%.

5. The method for preparing a contact lens according to claim 1, wherein: In step S1, the mass percentage concentrations of methacryloyl gelatin, lithium phenyl-2,4,6-trimethylbenzoylphosphinate and amniotic membrane powder in the mixed solution are 6-8%, 0.2-0.5% and 20-50% respectively.

6. The method for preparing a contact lens according to claim 1, wherein: In step S3, the mass percentage concentrations of methacrylated gelatin and lithium phenyl-2,4,6-trimethylbenzoylphosphinate in the contact lens treatment solution are 6-8% and 0.2-0.5%, respectively.

7. The method for preparing a contact lens according to claim 1, wherein: In step S4, the contact lens is completely immersed in the contact lens treatment solution at 15-40° C. for 20-60 minutes.

8. The method for preparing a contact lens according to claim 1, wherein: In step S5, the conditions of illumination are: wavelength 320 to 400 nanometers, and illumination for 30 to 120 seconds.

9. An amniotic membrane-loaded contact lens prepared according to the method for preparing an amniotic membrane-loaded contact lens according to claims 1-8.

10. The method for preparing the amniotic membrane-loaded contact lens according to claims 1 to 8 and the use of the amniotic membrane-loaded contact lens according to claim 9 in preparing a medical device for treating or alleviating corneal epithelial defects and promoting corneal epithelial cell repair.

Images